drugset / Trial / NCT07223697
A Long Term Extension Study to Evaluate the Safety and Efficacy of Afimkibart (RO7790121) in Participants With Atopic Dermatitis
Non-randomizedParallel-groupQuadruple-blindTreatment
Summary
This study will assess long-term safety and efficacy of Afimkibart (also known as RO7790121) in participants with Atopic Dermatitis (AD) who participated in previous afimkibart clinical trials.
Timeline
- Start
- 2026-01-08
- Primary completion
- 2033-03-01
- Completion
- 2033-03-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Afimkibart | Monoclonal antibody | — | Subcutaneous |